Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

14.07 -7.89 (-35.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Sarepta Therapeutics Provides Statement on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier
Via Stocktwits
Top stock movements in today's session.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Stocks Slip As Netflix Fails To Impress, Bitcoin Eyes Negative Week: What's Moving Markets Friday?
It’s a cautious end to the week on Wall Street, as earnings from Netflix Inc. (NASDAQ:NFLX) failed to impress investors. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market
The FDA had already been investigating two earlier deaths linked to Elevidys. 
Via Stocktwits
Topics Death
Friday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
Sarepta's Setback Deepens With Another Gene Therapy Fatality
Sarepta's gene therapy pipeline faces renewed scrutiny after a third patient death and FDA plans for a black box warning on Elevidys. 
Via Benzinga
Gapping stocks in Friday's session
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Sarepta Therapeutics Crashes 26% After A Third Gene Therapy Patient Dies
The move wiped out all of the gains Sarepta lodged Thursday after announcing its restructuring plans. 
Via Investor's Business Daily
Topics Death Stocks
Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Get insights into the top gainers and losers of Friday's pre-market session.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the... 
Via Benzinga
Topics Death
Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals. 
Via Benzinga
AAR, Lucid Group, Monarch Casino & Resort And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Assessing Sarepta Therapeutics: Insights From 35 Financial Analysts
Via Benzinga
Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
What's going on in today's pre-market session
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sarepta To Lay Off 500 Employees After Two Patient Deaths; Shares Catapult
The company is also restructuring with the hopes of saving $400 million in expenses. 
Via Investor's Business Daily
Topics Death Earnings Government
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.